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Background: Sepsis is a life-threatening organ dysfunction caused by a dysregulated host 
response to infection. Biologically active adrenomedullin (bio-ADM) is an emerging bio-
marker for sepsis. We explored whether bio-ADM concentration could predict severity, or-
gan failure, and 30-day mortality in septic patients.
Methods: In 215 septic patients (109 patients with sepsis; 106 patients with septic shock), 
bio-ADM concentration was measured at diagnosis of sepsis, using sphingotest bio-ADM 
(Sphingotec GmbH, Hennigsdorf, Germany) and analyzed in terms of sepsis severity, va-
sopressor use, and 30-day mortality. The number of organ failures, sequential (sepsis-re-
lated) organ failure assessment (SOFA) score, and 30-day mortality were compared ac-
cording to bio-ADM quartiles.
Results: Bio-ADM concentration was significantly higher in patients with septic shock, va-
sopressor use, and non-survivors than in patients with solitary sepsis, no vasopressor use, 
and survivors, respectively (all P <0.0001). Bio-ADM quartiles were associated with the 
number of organ failures (P <0.0001), as well as SOFA cardiovascular, renal, coagulation, 
and liver subscores (all P <0.05). The 30-day mortality rate showed a stepwise increase in 
each bio-ADM quartile (all P <0.0001). Bio-ADM concentration and SOFA score equally 
predicted the 30-day mortality (area under the curve: 0.827 vs 0.830).
Conclusions: Bio-ADM could serve as a useful and objective biomarker to predict severity, 
organ failure, and 30-day mortality in septic patients.
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INTRODUCTION
Sepsis is a life-threatening organ dysfunction caused by a dys-
regulated host response to infection. Septic shock is a subset of 
sepsis, in which underlying circulatory and cellular metabolic 
abnormalities are profound enough to substantially increase 
mortality [1]. The Third International Consensus Definitions for 
Sepsis and Septic Shock (Sepsis-3) identify organ dysfunction 
as an acute change in the total sequential (sepsis-related) organ 
failure assessment (SOFA) score ≥2 points [1]. The SOFA scor-
ing system has been used to describe organ dysfunction and 
failure in septic patients since first introduced in 1996 [2]. A 
higher SOFA score for each organ is associated with an increased 
probability of mortality [1, 2].
However, SOFA score could not be used to separate mortality 
in terms of cardiovascular status and coagulation system in the 
European-North American Study of Severity Systems [3, 4]. Al-
though it is preferable to avoid treatment-related criteria, the 
SOFA cardiovascular subscore is based on the requirement for 
adrenergic support, and the type of adrenergic support may dif-
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fer across institutions [2, 5]. Considering these innate limitations 
of the SOFA scoring system, it remains necessary to find a sub-
stitute for it or modify its use in evaluating septic patients, by us-
ing objective and reliable biomarkers.
Adrenomedullin (ADM), a newly identified neurohormonal 
system, is a 52-amino acid vasoactive peptide hormone that is 
encoded by the ADM gene on chromosome 11p15.4, contain-
ing four exons and three introns in humans [6-8]. ADM is ex-
pressed in all tissues, mainly by endothelial cells and vascular 
smooth muscle cells, and can regulate vasodilation and vascu-
lar integrity [7, 8]. The endogenous ADM concentration increases 
nonspecifically under various conditions, such as over-hydra-
tion, hypertension, ischemia, septic shock, and endocrine and 
metabolic disorders [5, 9-11]. ADM has emerged as an inde-
pendent prognostics biomarker especially in heart failure and/or 
sepsis [5, 12-14].
Recently, a double monoclonal sandwich immunoassay has 
been developed to measure C-terminal amidated biologically 
active ADM (bio-ADM) [15]. Recent studies have demonstrated 
the association between bio-ADM concentration and hemody-
namic support requirement, as well as its short-term prognostic 
values in sepsis [16-18]. We explored whether bio-ADM con-
centration could predict sepsis severity, organ failure, and 30-
day mortality in septic patients. We hypothesized that bio-ADM 
could play a prognostic role in sepsis and serve as a potential 
substitute for the SOFA score in evaluating septic patients.
METHODS
Study population
A total of 245 consecutive patients were diagnosed as having 
sepsis according to the Sepsis-3 definition at Konkuk University 
Medical Center (KUMC), Seoul, Korea, from August 2016 to 
August 2017 [1]. After excluding 30 patients without available 
leftover samples, we recruited 215 patients; 109 patients (50.7%) 
were diagnosed as having sepsis and 106 patients (49.3%) were 
diagnosed as having septic shock. These patients received pro-
per and standard-of-care treatment according to the guidelines 
[19, 20]. Their medical records were reviewed retrospectively 
for demographic, laboratory, and clinical data, including age, 
sex, hospital stay, comorbidities, and clinical outcomes. The 
baseline characteristics of the study population are summarized 
in Table 1.
This registry study protocol was approved by the Institutional 
Review Board of KUMC, prior to the collection of the first sam-
ple from the first patient. This study did not require any study-
Table 1. Basic characteristics of the study population
Variable
All patients 
(N=215)
Sepsis 
(N=109)
Septic shock 
(N=106)
Patients enrollment
   ICU* 92 (42.8) 22 (20.2) 70 (66.0)
   Emergency department 123 (57.2) 87 (79.8) 36 (34.0)
Age (yr) 71 (58–79) 70 (58–79) 72 (59–79)
Males 127 (59.1) 65 (59.6) 62 (58.5)
Hospital stay (days) 15 (6–31) 15 (7–28) 16 (5–43)
Comorbidities
   Cardiovascular 116 (54.0) 68 (62.4) 48 (45.3)
   Cerebrovascular 115 (45.1) 51 (46.8) 64 (60.3)
   Renal and genitourinary 60 (27.9) 36 (33.0) 24 (22.6)
   Gastrointestinal 20 (7.8) 8 (7.3) 12 (11.3)
   Respiratory 20 (7.8) 11 (10.1) 9 (8.5)
   Hemato-oncological 8 (3.1) 5 (4.6) 3 (2.8)
   Others 7 (3.3) 3 (2.8) 4 (3.8)
Type of infections
   Bacteremia 214 (99.5) 108 (99.1) 106 (100.0)
   Respiratory 98 (41.7) 43 (39.4) 55 (51.9)
   Urinary 63 (26.8) 37 (33.9) 26 (24.5)
   Gastrointestinal 56 (23.8) 23 (25.7) 33 (31.1)
   Soft tissue 10 (4.3) 8 (7.3) 2 (1.9)
   Others 7 (3.0) 4 (3.7) 3 (2.8)
SOFA score 7 (4–10) 5 (3–8) 13 (10–15)
   Cardiovascular 3 (0–4) 0 (0–1) 4 (4–4)
   Central nervous system 0 (0–2) 0 (0–1) 2 (0–3)
   Coagulation 1 (0–2) 1 (0–2) 2 (0–2)
   Liver 0 (0–1) 0 (0–1) 1 (0–2)
   Renal 1 (0–2) 1 (0–2) 1 (1–2)
   Respiratory 3 (1–4) 1 (0–3) 4 (2–4)
Laboratory parameters
   WBC (×109/L) 12.8 (6.8–16.9) 11.8 (6.7–15.1) 14.6 (7.2–20.1)
   CRP (mg/dL) 16.2 (10.2–25.4) 15.7 (9.2–22.5) 18.4 (11.5–27.0)
   Lactate (mmol/L) 3.56 (2.00–6.04) 2.03 (1.38–3.34) 4.89 (3.71 –9.55)
   Creatinine (mg/dL) 1.58 (0.95–2.82) 1.29 (0.85–2.78) 1.85 (1.16–2.87)
   Procalcitonin (ng/mL) 17.7 (6.5–44.4) 13.7 (5.1–24.4) 26.7 (8.7–68.1)
Data are expressed as number (percentage) or median (interquartile range).
*The 92 ICU patients were enrolled from medical (N=60, 65.2%), surgical 
(N=24, 26.1%), and neurological (N=8, 8.7%) ICUs.
Abbreviations: ICU, intensive care unit; SOFA, sequential organ failure as-
sessment; WBC, white blood cells; CRP, C-reactive protein.
intended blood sampling or other interventions. In all septic pa-
tients, routine laboratory parameters were measured on the day 
when the patients were diagnosed as having sepsis; the SOFA 
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score was assessed on the same day (within 24 hours of sepsis 
diagnosis) in six different organ systems (respiratory, cardiovas-
cular, hepatic, coagulation, renal, and neurological) and as-
signed a value from zero (normal) to four (high degree of failure) 
[2]. Residual blood samples were collected for measuring bio-
ADM concentration. Attending clinicians (in the intensive care 
unit [ICU] or emergency department [ED]) made a clinical diag-
nosis of sepsis according to the Sepsis-3 definitions [1], decided 
on the enrollment of the patients in this study, and then in-
formed the laboratory to store residual EDTA plasma after rou-
tine blood testing. Therefore, written informed consent from the 
patients was exempted.
Assay
The samples were split into small aliquots to avoid repeated 
freezing and thawing, frozen within two hours, and stored at 
-70°C until use. Frozen samples were sent to the reference lab-
oratory (Sphingotec GmbH, Hennigsdorf, Germany) after being 
anonymized and blinded, and then thawed at room temperature 
and gently mixed for at least 30 minutes just before measuring 
bio-ADM concentration. Plasma bio-ADM concentrations were 
measured according to the manufacturer’s instructions as de-
scribed previously [11, 16, 21]. Briefly, this is a one-step sand-
wich chemiluminescence immunoassay based on acridinium 
NHS-ester labeling for the detection of human ADM in unpro-
cessed plasma, which uses two mouse monoclonal antibodies: 
one directed against the middle region of ADM (solid phase) 
and the other directed against the amidated C-terminal moiety 
of ADM (labeled antibody). The immunoassay employs 50-μL 
plasma samples or calibrators and 200 µL labeled detection an-
tibody (800,000 relative light units per 200 µL). The sample and 
antibody are added to the coated tubes, incubated for 18 hours 
at 4°C, and washed five times with washing solution (1 mL each). 
Next, chemiluminescence is measured for one second using an 
LB953 Multi-Tube Luminometer (Berthold Technologies GmbH 
& Co KG, Bad Wildbad, Germany) [22]. The analytical sensitiv-
ity is 2 pg/mL; the median concentration of bio-ADM based on 
200 reference individuals was 20.7 pg/mL, and the 99th per-
centile was 43 pg/mL [16, 23]. The manufacturer-claimed and 
previously reported medical decision point is 70 pg/mL [16, 17, 
21, 23].
Statistical analysis
Data were generated as median and interquartile range (IQR) or 
number and percentage. Mann-Whitney test was used to com-
pare two patient groups according to sepsis severity (sepsis vs 
septic shock), vasopressor use, and survival. The chi-squared 
test was used to compare bio-ADM quartile groups (from Q1 to 
Q4) according to the number of organ failures included in the 
SOFA scoring system (from zero to six) and SOFA subscores.
The chi-squared test was also used to compare the 30-day 
mortality rate according to bio-ADM quartiles, SOFA cardiovas-
cular subscores, and lactate quartiles. Kaplan-Meier survival 
curves and hazard ratios (HRs) with 95% confidence intervals 
(CIs) were compared between each group created according to 
bio-ADM quartile, SOFA cardiovascular subscore, and lactate 
quartile for predicting 30-day mortality. The patients were divided 
into two groups using the medical decision point of 70 pg/mL, 
and Kaplan-Meier survival analysis was performed to compare 
these two groups for predicting 30-day mortality. These analyses 
were conducted for all patients as well as within the sepsis and 
septic shock groups.
ROC curves of bio-ADM concentration and SOFA score were 
used to derive the optimal cut-off values to predict 30-day all-
cause mortality; optimal cut-off values were indicated where the 
sum of the false positive and false negative results was lowest. 
Using optimal cut-off values, the areas under the curves (AUC) 
were compared with their 95% CIs. Cox proportional hazard re-
gression was used to analyze the effect of bio-ADM concentra-
tion and SOFA score on 30-day all-cause mortality; univariate 
relative risk (RR) with 95% CI of the variables and P values were 
obtained.
MedCalc Statistical Software version 18.6 (MedCalc Software 
Bvba, Ostend, Belgium) and R version 3.3.1 (R Foundation for 
Statistical Computing, Vienna, Austria) were used for statistical 
analyses. P values were not adjusted for multiple comparisons 
and therefore were only descriptive.
RESULTS
Prediction of sepsis severity and organ failure
Bio-ADM concentration was significantly higher in septic shock 
patients than in septic patients (110.3 vs 45.3 pg/mL, P <0.0001), 
in patients with vasopressor use than in patients without vaso-
pressor use (99.3 vs 44.0 pg/mL, P <0.0001), and in non-survi-
vors than in survivors (137.8 vs 55.3 pg/mL, P <0.0001) (Fig. 
1). In all three comparisons, median bio-ADM concentrations 
were higher than the 70 pg/mL medical decision point in patients 
with septic shock, vasopressor use, and in non-survivors.
Bio-ADM concentrations were divided into quartiles: Q1<36.5 
pg/mL (N=54); 36.5 pg/mL≤Q2<75.8 pg/mL (N=54); 75.8 
pg/mL≤Q3<139.0 pg/mL (N=53); and Q4≥139.0 pg/mL (N= 
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54). Bio-ADM quartiles were significantly associated with the 
number of organ failures (P <0.0001) (Fig. 2A) and with SOFA 
cardiovascular, renal, coagulation, and liver subscores, but not 
with SOFA respiratory and central nervous system subscores 
Fig. 1. Comparison of bio-adrenomedullin (bio-ADM) concentrations according to sepsis severity (A), vasopressor use (B), and survival (C). 
In each figure, the Y axis is presented as a logarithmic scale, and the red line indicates the medical decision point (70 pg/mL) of bio-ADM.
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(Fig. 2B; data not shown). Bio-ADM quartiles were associated 
with SOFA renal subscore in patients with sepsis and with SOFA 
renal and coagulation subscores in patients with septic shock 
(data not shown).
Prediction of 30-day mortality 
The 30-day mortality rate in each bio-ADM quartile group showed 
a stepwise increase: 5.6% in Q1, 11.1% in Q2, 45.3% in Q3, 
and 61.1% in Q4. In addition to all patients, significant increase 
was also observed in each sepsis and septic shock patient group 
(all P <0.0001; data not shown). Bio-ADM quartile groups could 
stratify the survival probability, and the HRs were significantly 
higher when bio-ADM Q3 and Q4 groups were compared with 
Q1 and Q2 groups (HR=8.7 in Q3 vs Q1; HR=4.7 in Q3 vs Q2; 
HR=11.9 in Q4 vs Q1; and HR=6.4 in Q4 vs Q2 group). In ad-
dition to all patients, this significant finding was also observed 
within the sepsis and septic shock patients (P <0.0001; P <0.0001; 
P =0.0006) (Fig. 3A, 3B, and 3C). When bio-ADM concentra-
tions were stratified using the medical decision point of 70 pg/
mL, the 30-day mortality rate also differed significantly between 
the two groups in all patients as well as within the sepsis and 
septic shock patient groups (HR=7.0, 5.2, and 6.3, respectively) 
(Fig. 3D, 3E, and 3F).
The SOFA cardiovascular subscores and lactate quartiles strati-
fied the survival probability in all patients (P =0.0001 and P < 
0.0001, respectively) (Fig. 4). When patients were divided into 
sepsis and septic shock groups, only the lactate quartiles in pa-
tients with septic shock showed a significant stratification (data 
not shown). Bio-ADM concentration and SOFA score were simi-
lar in predicting 30-day mortality (AUC, 0.827 vs 0.830, P =0.918); 
the RR of bio-ADM concentration was higher than that of SOFA 
score (RR=3.6 and 1.2, respectively; Table 2).
Table 2. Comparison of bio-adrenomedullin (ADM) concentration and sequential organ failure assessment (SOFA) score for predicting 30-
day mortality
ROC curve analysis Cox proportional hazard regression
Cut-off value Sensitivity (95% CI) Specificity (95% CI) AUC (95% CI)* Relative risk (95% CI) P
bio-ADM 97.13 pg/mL 77.3 (65.3–86.7) 79.9 (72.5–86.0) 0.827 (0.770–0.875) 3.6† (1.6–7.9) <0.0001
SOFA score 12 66.7 (54.0–77.8) 87.3 (80.8–92.1) 0.830 (0.774–0.878)  1.2 (1.1–1.2)     0.0015
*P =0.918 for pairwise comparison of ROC curves; †Medical decision point was 70 pg/mL.
Abbreviations: bio-ADM, bio-adrenomedullin; CI, confidence interval; AUC, area under the curve; SOFA, sequential (sepsis-related) organ failure assessment.
Fig. 2. Number of organ failures (A) and distribution of sequential (sepsis-related) organ failure assessment (SOFA) cardiovascular sub-
score (B) according to bio-adrenomedullin (bio-ADM) quartiles.
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DISCUSSION
We explored the clinical utility of bio-ADM as an objective bio-
marker equivalent to SOFA score for assessing organ failure and 
predicting mortality in septic patients. We observed that bio-
ADM concentration was significantly associated with septic 
shock, vasopressor use, and 30-day mortality (Fig. 1). In addi-
tion, bio-ADM quartiles showed a stepwise increase in the num-
Fig. 3. Prediction of 30-day mortality in sepsis using bio-ADM quartiles (A-C) and medical decision point (70 pg/mL) (D-F).
Abbreviations: bio-ADM, bio-adrenomedullin; HR, hazard ratio. (Continued to the next page)
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ber of organ failures, and elevated bio-ADM concentration was 
associated with specific organ failures, especially in terms of 
SOFA cardiovascular, renal, coagulation, and liver subscores 
(Fig. 2).
Multiple organ failure is a complex syndrome involving diverse 
pathways and pathological processes in sepsis [24, 25]. Cardiac 
failure is a major risk factor of in-hospital mortality [26]. In addi-
tion, cardiac and renal diseases interact in a complex bidirec-
tional and interdependent manner in both acute and chronic 
settings; sepsis is a representative disease entity of the organ 
Fig. 3. Continued.
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crosstalk between the heart and kidney [24]. Because conges-
tion is the main cause for worsening heart failure, the 2016 Eu-
ropean Society of Cardiology heart failure guidelines recommend 
daily evaluation of signs of congestion [27]. In clinical practice, 
however, frequent assessment of congestion is difficult, and the 
assessment is often considered unreliable because of consider-
able inter-observer variability. Therefore, there is a need for a 
rapid, reliable, and objective tool to assess and monitor patient’s 
heart failure; bio-ADM is an emerging biomarker for predicting 
acute circulatory failure [28-30]. Our data shows that bio-ADM 
can simply and objectively reveal sepsis-induced organ failure 
in circulation and has the potential to serve as a substitute for 
SOFA subscores.
Bio-ADM quartiles, SOFA cardiovascular subscore, and lac-
tate quartiles all showed significant association with 30-day mor-
tality rate. Of note, bio-ADM and lactate quartiles indicated a step-
wise increase in the 30-day mortality rate; however, the SOFA 
cardiovascular subscore could not separate the 30-day mortality 
rate in a stepwise pattern (Figs. 3 and 4). This finding is in line 
with the original study on the SOFA scoring system [2]. More re-
markably, when patients were divided into sepsis and septic 
shock groups, bio-ADM quartiles could consistently predict and 
stratify 30-day mortality. Interestingly, very high bio-ADM con-
centrations in sepsis without shock identified patients with a 
very high mortality risk (despite not having shock), whereas very 
low bio-ADM concentrations in septic shock identified patients 
with a low mortality risk. This finding may be clinically impor-
tant. However, neither SOFA cardiovascular subscore nor lactate 
quartiles could show such a finding. The lactate quartiles were 
associated with 30-day mortality in patients with septic shock; 
given that the current definition of septic shock is based on lac-
tate concentration, this finding was expected in this patient group. 
Taken together, it seems that the measurement of bio-ADM con-
centration could provide added value to the treatment-related 
SOFA cardiovascular subscore and lactate concentration in pre-
dicting 30-day mortality.
Regarding the suggested medical decision point of bio-ADM, 
Marino et al. [23] showed that a high 28-day mortality rate was 
noted for European patients who were admitted with bio-ADM 
concentrations >70 pg/mL. In our study on an Asian popula-
tion, the clinical bio-ADM value was also useful in identifying 
patients with an increased mortality risk, as well as the need for 
vasopressor therapy; our findings support the usefulness of this 
bio-ADM clinical value regardless of ethnicity [16, 17, 23].
Our study was limited in that it was a small-sized, single-cen-
ter registry study; therefore, sepsis severity and mortality could 
differ from those of other population cohorts. Second, the SOFA 
cardiovascular subscore was based on the requirements for ad-
renergic support; although the enrolled patients received stan-
dardized treatment, treatment may vary across institutions or 
countries. Third, we could not maintain a standardized sam-
pling time or define the exact time delay from sepsis diagnosis 
to plasma sampling, although it was done within 24 hours. The 
half-life of plasma bio-ADM is known to be approximately 20 
minutes; as a biomarker of acute cardiovascular failure, bio-ADM 
could have significantly changed during the first 24 hours after 
sepsis diagnosis. In recent studies, serial measurements of bio-
ADM concentrations indicated a survival benefit in patients with 
decreased bio-ADM concentrations at subsequent measure-
ments [16, 17, 31, 32]. Observation of a delta change would 
have further clarified the clinical significance of bio-ADM. Fourth, 
we did not evaluate the correlation of bio-ADM with proadreno-
medullin (proADM), which has been extensively researched in 
sepsis and other critical settings; more bio-ADM studies (similar 
to the proADM studies) aimed at improving patient triage are 
necessary [33, 34].
Despite these limitations, we provide evidence that bio-ADM 
concentration was associated with sepsis severity, organ failures, 
vasopressor use, and short-term mortality in patients with sepsis 
and septic shock. Bio-ADM concentration and SOFA score simi-
larly predicted 30-day mortality, with the assumption of a greater 
effect of bio-ADM concentration. Bio-ADM quartiles seem to be 
superior to SOFA cardiovascular subscore and lactate quartiles 
for predicting and stratifying 30-day mortality in each sepsis and 
septic shock patient group. Thus, bio-ADM could serve as a 
useful and objective biomarker that can substitute for or modify 
the current role of the SOFA scoring system in evaluating septic 
patients. Further large-scale studies are needed to support our 
findings.
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